Golidocitinib monotherapy showed high and durable response in adults with secondary HLH, to be featured in an oral presentation. Two oral presentations showing superior clinical benefits of birelentinib, as a single agent or in combination with a BCL2 inhibitor, in 1st line CLL/SLL...